København S
København S
København S, Denmark4 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | Arterial Occlusive Diseases, Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, nutritional disorder, obesity disorder, overnutrition, vascular disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07037433 | |
| Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Phase 3 | 2026-09-18 | NCT07181109 | |
| PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications, Fetal Diseases, Hemic and Lymphatic Diseases, Hemorrhage, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, Obstetric Labor Complications, Obstetric Labor, Premature, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postpartum Hemorrhage, Urogenital Diseases, Uterine Hemorrhage, cardiovascular disorder, diabetes mellitus, endocrine system disorder, fetal growth restriction, follicular lymphoma, gestational diabetes, glucose metabolism disease, hereditary endocrine growth disease, hypertension, pregnancy-induced, hypertensive disorder, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, metabolic disease, neoplasm, placenta disorder, placental abruption, preeclampsia, pregnancy disorder, puerperal disorder, vascular disorder | Recruiting | Not stated | 2026-04-13 | NCT07263490 | |
| Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-02-27 | NCT05581303 |